Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | CLK1 | P49759 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4687548 | 0.79 | FFAR2 (0.74) | FFAR2MAPK1LMNASMN1; SMN2POLB | |
| SCHEMBL23657933 | 0.77 | PRKACA (0.61) | FFAR2MAPK1LMNASMN1; SMN2POLB | |
| SCHEMBL11627595 | 0.77 | ROCK1 (0.61) | FFAR2MAPK1LMNASMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL29855979 | 0.77 | FFAR2 (0.72) | FFAR2MAPK1LMNASMN1; SMN2POLB | |
| SCHEMBL6958155 | 0.77 | KDM4E (0.49) | FFAR2MAPK1LMNASMN1; SMN2POLB | |
| SCHEMBL10915238 | 0.76 | FFAR2 (0.58) | FFAR2MAPK1LMNASMN1; SMN2POLB | |
| SCHEMBL1564971 | 0.75 | MAPT (0.50) | FFAR2MAPK1LMNAPOLBMAPT | |
| SCHEMBL8609550 | 0.75 | FFAR2 (0.67) | FFAR2MAPK1LMNASMN1; SMN2POLB | |
| SCHEMBL1565806 | 0.74 | MAPT (0.49) | FFAR2MAPK1POLBALDH1A1MAPT | |
| SCHEMBL2654801 | 0.74 | MAPT (0.49) | FFAR2MAPK1POLBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1121361-A1 | PYRAZOLO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | Merck Sharp & Dohme Limited (GB) | 2001-08-08 | — | — | EP | claimed |
| WO-2000023449-A1 | PYRAZOLO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2000-04-27 | — | — | WO | claimed |
| EP-1305301-B1 | ALPHA-ACYL AND ALPHA-HETEROATOM-SUBSTITUTED BENZENE ACETAMIDE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-6608218-B2 | Such as 1-(cyclopentyloxy-(3,4-dichloro-phenyl)-acetyl)-3-methyl-urea for treatment of diabetes | HOFFMANN-LA ROCHE INC. | 2003-08-19 | — | — | US | disclosed |
| EP-1305301-A1 | ALPHA-ACYL AND ALPHA-HETEROATOM-SUBSTITUTED BENZENE ACETAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-02 | — | — | EP | disclosed |
| US-20020198200-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | KESTER ROBERT F (US) | 2002-12-26 | — | — | US | disclosed |
| US-6486184-B2 | 1-(CYCLOPENTYLOXY-(3,4-DICHLORO- PHENYL)-ACETYL)-3-METHYL-UREA FOR EXAMPLE; USE IN TREATING HYPERGLYCEMIA CHARACTERISTIC OF ALL TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-11-26 | — | — | US | disclosed |
| US-20020042512-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | KESTER ROBERT F (US) | 2002-04-11 | — | — | US | disclosed |
| WO-2002008209-A1 | ALPHA-ACYL AND ALPHA-HETEROATOM-SUBSTITUTED BENZENE ACETAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042512-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | GCK, GCKR, ALDOA | FFAR2 1362/4885MAPK1 2943/4885LMNA 4429/4885 |
| US-20020198200-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | GCK, GCKR, ALDOA | FFAR2 1356/4885MAPK1 2854/4885LMNA 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.